What is happening inside the brain
Alzheimer's is not simply memory loss. It is a progressive neurodegenerative disease driven by compounding biological processes that begin years, sometimes decades, before any symptoms appear. Here is what is actually happening, in plain language.
Buildup in the foundation: amyloid plaques accumulate
A protein fragment called beta-amyloid is normally produced and cleared by the brain. In Alzheimer's, that clearance fails, so fragments cluster into sticky plaques between neurons. Neurons are the MVPs of chemical signaling, and plaques can disrupt their transmissions. Disruption originates in the hippocampus, which is why memory is the first place we see the cracks.
Where the wires get crossed: tau tangles form inside neurons
Tau is a protein that stabilizes the internal transport system of neurons. Think of it as the tracks a train runs on. In Alzheimer's, tau becomes abnormally phosphorylated and forms tangles inside cells. The transport system collapses. Neurons can no longer receive nutrients or remove waste, and they die.
Signs of wear and tear: neuroinflammation amplifies the damage
The brain's immune cells, called microglia, detect plaques and tangles and mount an inflammatory response. That response leaves the system in a constant state of dysregulation. What is meant to protect begins to damage surrounding tissue, accelerating neuron loss in a compounding cycle.
The floorboards crack: neurotransmitter systems break down
As neurons die, the chemical messengers they produce decline. Acetylcholine, critical for memory and learning, drops significantly. Glutamate dysregulation also occurs, driving excitotoxicity in surviving neurons.
This is where the first generation of Alzheimer's treatments comes in. Cholinesterase inhibitors like Donepezil (Aricept) slow the breakdown of acetylcholine to preserve what remains. Memantine (Namenda) targets the glutamate pathway to protect surviving neurons from further damage. Both are symptomatic treatments, meaning they manage the experience of the disease without changing its underlying course.
Repairing The Home: Clearing Amyloid Directly
Lecanemab (Leqembi) and donanemab (Kisunla) represent a paradigm shift. These are anti-amyloid monoclonal antibodies that bind to amyloid plaques and recruit the immune system to clear them. They do not reverse damage already done, but in early-stage disease they have shown measurable slowing of clinical decline. This is the first class of treatments targeting the underlying biology, not just the symptoms.
For people experiencing agitation associated with Alzheimer's dementia, REXULTI (brexpiprazole) received FDA approval in 2023 as the first treatment specifically approved for this indication. Developed by Otsuka, it works as a serotonin-dopamine activity modulator, addressing the behavioral disruptions that often accompany cognitive decline and significantly affect quality of life for both patients and caregivers.
Symptomatic vs. Disease-Modifying
Older treatments manage symptoms by supporting failing neurotransmitter systems. They do not change the underlying course of disease. Newer anti-amyloid therapies aim to modify the disease itself, slowing the biological process, not just the experience of it. Both categories have a role, and the right approach depends entirely on stage and eligibility. Ask your neurologist which tier applies to your situation right now.
How to read a trial
Before any study: three questions that matter. Who was in the population? What was being measured as the endpoint? And how large was the effect in real-world terms, not just statistical significance? These questions apply to every study your doctor mentions.
Compared lecanemab (IV infusion every two weeks) against placebo in patients with early Alzheimer's confirmed by amyloid PET or cerebrospinal fluid biomarkers. Biomarker confirmation was required to enroll, which is clinically important.
Context to hold: the 27% difference is statistically significant but modest in absolute terms. ARIA, meaning amyloid-related imaging abnormalities including brain swelling or microbleeds, occurred in approximately 21% of patients and requires MRI monitoring throughout treatment. Benefits are clearest in very early disease with confirmed amyloid positivity.
Patients were stratified by tau burden (low/medium versus high). Treatment could stop once amyloid was cleared, a novel adaptive design not seen in prior Alzheimer's trials. FDA approved July 2024.
Context to hold: tau stratification changes who the optimal candidate is, which is why biomarker testing matters before assuming eligibility. ARIA rates were similar to lecanemab. The stop-when-clear design has important long-term safety implications the field is watching closely.
Two Phase 3 trials evaluated brexpiprazole versus placebo specifically for agitation associated with dementia due to Alzheimer's disease. REXULTI became the first FDA-approved treatment for this indication in May 2023.
Context to hold: REXULTI carries a boxed warning for increased risk of death in elderly patients with dementia-related psychosis. It is approved specifically for agitation, not for dementia-related psychosis without agitation. Ongoing MRI monitoring is not required, but regular clinical review is essential.
Long-term follow-up of donepezil versus placebo across mild to moderate Alzheimer's. One of the most foundational studies in Alzheimer's clinical practice.
Questions to ask about any study your doctor mentions
Was the study population similar to me in stage, age, and biomarker profile? Results from early-stage trials may not apply to moderate or advanced disease.
What was the primary endpoint and does it reflect what we actually care about? Statistical significance is not the same as meaningful benefit in daily life.
What were the most serious adverse events and how were they managed? Especially for anti-amyloid therapies, ARIA requires active monitoring.
Is this available outside a trial, or does participation require enrollment? Ask what the eligibility workup involves before assuming access.
Fill this out before appointments
The more specific you are, the more useful this becomes as a shared document between you, your neurologist, and any other providers. Save or print it after completing each section.
The full picture of your care
Alzheimer's care does not begin and end at the prescription pad. Share this section with your neurologist, your functional medicine practitioner, your acupuncturist, your herbalist, or whoever is part of your care circle. The goal is coordination, not competition.
Nutritional and metabolic support
The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) has the strongest observational evidence for brain health, built around leafy greens, berries, nuts, olive oil, fish, and whole grains. Beyond diet structure, metabolic health matters: insulin resistance and chronic inflammation are increasingly recognized as contributors to cognitive decline. Ask your integrative provider about testing fasting insulin, CRP, and Vitamin D alongside standard labs.
Herbal and botanical support
Several botanicals have emerging or traditional evidence for cognitive and neurological support, and all carry real contraindication profiles that your medical team needs to know about. None should be added without disclosure to your prescribing physician, particularly around procedures or active treatment.
Botanicals commonly discussed in integrative Alzheimer's care include: Lion's Mane mushroom (Hericium erinaceus), studied for nerve growth factor stimulation; Bacopa monnieri, an Ayurvedic herb with small trial evidence for memory; Ginkgo biloba, long used for circulation and cognitive support with mixed but notable trial data; Ashwagandha (Withania somnifera), for stress and cortisol regulation; and turmeric/curcumin for its anti-inflammatory properties. Product quality varies enormously. Third-party tested formulations only.
Nervous system regulation and somatic practices
Chronic stress and cortisol dysregulation accelerate neurodegeneration. Nervous system regulation is not a soft recommendation; it is a physiological one. Practices with real evidence include: breathwork and diaphragmatic breathing for vagal tone; yoga and tai chi for body-based stress discharge and balance; meditation for cortisol reduction and prefrontal cortex support; and somatic movement practices that help both patient and caregiver discharge accumulated stress. For caregivers especially, this is not optional. A dysregulated caregiver cannot create a regulated environment.
Ayurvedic and traditional medicine perspectives
Ayurveda views cognitive decline through the lens of Vata imbalance, a depletion of the air and space elements that govern movement, communication, and the nervous system. Traditional approaches focus on grounding, warming, and nourishing practices: daily abhyanga (self-massage with warm oil, particularly sesame), Brahmi and Shatavari as nervine tonics, consistent sleep and meal timing aligned with circadian rhythms, and reducing sensory overstimulation. These practices are low-risk and deeply complementary to conventional care when guided by a qualified Ayurvedic practitioner. They can also be profoundly comforting for both patient and family.
Acupuncture, bodywork, and energy medicine
Acupuncture has a growing evidence base for pain, anxiety, and sleep in older adults, and is used clinically in integrative memory care programs. Massage therapy reduces agitation and improves sleep quality in Alzheimer's patients, with low risk and high tolerability. Reiki and therapeutic touch are used in palliative and dementia care settings for comfort and calming, with primarily experiential rather than clinical evidence. Craniosacral therapy is explored in some integrative settings for nervous system support. Bring any current or planned bodywork to your care team so they can flag any contraindications.
Meaning, ritual, and spiritual care
This is the tier most clinical frameworks leave out entirely, and it may be one of the most powerful. Meaning-making through spiritual practice, cultural ritual, creative expression, music, and community connection has documented effects on quality of life, treatment tolerance, and caregiver resilience. Music in particular has extraordinary evidence in Alzheimer's care: familiar music activates preserved long-term memory networks even in advanced stages, reducing agitation and improving mood and recognition. This is not soft care. It is the container that holds a person while medicine does its work.
Walk in prepared, not remembering
Check off each item before every appointment. The goal is to arrive knowing your priorities and leave with answers, not more fog.
My questions
Write your specific questions here before you go. Leave space to note the answers during the visit.
The most underprescribed interventions
These are not alternative medicine. They are the highest-value, lowest-risk tier of any Alzheimer's care plan, and the most consistently overlooked in clinical settings. The evidence is real. The access is immediate.
Aerobic exercise
The most robust non-pharmacological intervention in Alzheimer's research. Cardio increases BDNF (brain-derived neurotrophic factor), supports hippocampal volume, and reduces neuroinflammation. 150 minutes per week of moderate intensity is the target. Even walking counts. The evidence is dose-responsive, not all-or-nothing.
Sleep quality
The glymphatic system, the brain's waste clearance mechanism, operates primarily during deep sleep. Poor sleep directly impairs amyloid clearance. Sleep disruption is both a symptom and a driver of Alzheimer's progression. Treating sleep belongs in the core care plan alongside medications, not as an afterthought.
Mediterranean or MIND diet
The MIND diet was specifically designed for brain health. Multiple observational studies associate adherence with slower cognitive decline. Anti-inflammatory, rich in omega-3s, leafy greens, and polyphenols. Not a cure. A meaningful modifier that is low-risk and immediately actionable.
Social and cognitive engagement
Social isolation is a significant risk factor for accelerated decline. Cognitive engagement, including learning new things, meaningful conversation, and structured activities, builds cognitive reserve. This is not about puzzles. It is about staying in relationship with the world, with purpose and real connection.
Caregiver wellbeing: non-negotiable
Cortisol dysregulation accelerates neurodegeneration in the person with Alzheimer's, and caregiver burnout is a healthcare crisis inside the Alzheimer's crisis. Breathwork, therapy, peer support, and respite care are not soft add-ons. They are part of the treatment plan, and they belong here, in writing, as a priority.